New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence. TAIPEI, ...

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. The research ...

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE)-- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative ...

U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday. Shares of SL Science Holding Ltd SLBT fell sharply in pre-market trading after the company reported ...

"2025 was a highly transformative and foundational year for SL Science as we aggressively advanced our core cell therapy pipeline and executed our long-term strategic shift toward next-generation ...

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing ...

The ODD request was submitted pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Product: Vdelta2+ Gamma Delta T CellsDisease / Condition: Glioblastoma Multiforme ...

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE)-- SL Science Holding Limited ("SL Science” or the "Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative ...

SL Science Holding Ltd stock reached a 52-week low of $1.74, marking a significant downturn for the company. The stock has plummeted 88% from its 52-week high of $14.50, with the company now carrying ...

TAIPEI, TAIWAN, July 17, 2026 (GLOBE NEWSWIRE)-- SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, ...